Research from Chengdu Provide New Insights into COVID-19 (COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation)

MLA

“Research from Chengdu Provide New Insights into COVID-19 (COVID-19 Susceptibility and Severity for Dyslipidemia: A Mendelian Randomization Investigation).” Medical Letter on the CDC & FDA, 8 Oct. 2023, p. 441. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.767299789&authtype=sso&custid=ns315887.

APA

Research from Chengdu Provide New Insights into COVID-19 (COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation). (2023, October 8). Medical Letter on the CDC & FDA, 441.

Chicago

Medical Letter on the CDC & FDA. 2023. “Research from Chengdu Provide New Insights into COVID-19 (COVID-19 Susceptibility and Severity for Dyslipidemia: A Mendelian Randomization Investigation),” October 8. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.767299789&authtype=sso&custid=ns315887.